The Alpestria-1 study enrolled (in France, USA and Spain) 26 patients with Alport syndrome at high risk of a rapid loss of kidney function despite stable multiple SoC drugs, including ...

Phase 2 BESTOW trial data evaluating tegoprubart in kidney transplantation showed favorable efficacy, safety and tolerability, supporting ...

The firm began a Phase II study of evorpacept in HER2-positive breast cancer patients and began testing a higher dose of ALX2004 in a separate Phase I trial.

First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician’s choice of ...

EpiBiologics launched in 2023 with a $50 million series A, having been founded to take forward the work of renowned antibody ...

Three years after launching from the lab of University of California, San Francisco chemist Jim Wells, the start-up EpiBiologics has raised $109 million in series B funding to propel its ...

The startup is developing a medicine that can very specifically degrade cancerous forms of EGFR, the target of an array of ...

In Brazil, the early detection of genetic alterations in lung cancer through liquid biopsies could be a valuable tool for ...

-- Proceeds to drive global Phase 3 trial for ASP-1929, targeting BLA submission to the U.S. FDA in 2028 -- Financing led by international life science fund TaiAx, with participation from the largest ...

ArriVent BioPharma's furmonertinib demonstrates robust efficacy, CNS penetration, and tolerability in early trials. Read why ...

Rybrevant Faspro, the new subcutaneous version of amivantamab, was approved for patients with a specific form of lung cancer ...

Investing in dividend-paying stocks is one of numerous approaches that can help you maximize your portfolio growth, and provide you with extra income to save or reinvest as you desire. If you're ...